LivaNova plc has outlined a comprehensive strategic roadmap and long-range financial plan, targeting revenue and earnings-per-share growth through 2030. The company aims to leverage its leadership positions in the Epilepsy and Cardiopulmonary businesses to drive predictable growth, expand margins, and generate consistent cash flow. Key elements of the strategy include maximizing core business performance, scaling the Obstructive Sleep Apnea (OSA) segment, and maintaining potential upside in Difficult-to-Treat Depression $(DTD)$, pending Centers for Medicare & Medicaid Services $(CMS)$ coverage. LivaNova's Cardiopulmonary business will focus on capitalizing on replacement cycles, introducing a next-generation oxygenator by 2028, and expanding recurring revenues through software and services. Financial targets include achieving an adjusted annual operating margin above 20% over the next three years, reaching the high twenties by 2030, maintaining adjusted free cash flow conversion above 80%, and delivering a low double-digit to mid-teens earnings-per-share compound annual growth rate.